<DOC>
	<DOCNO>NCT02779699</DOCNO>
	<brief_summary>To study pharmacokinetic characteristic AL2846 human body , recommend reasonable regimen subsequent research .</brief_summary>
	<brief_title>A Study AL2846 Tolerance Pharmacokinetics</brief_title>
	<detailed_description />
	<criteria>Histological documentation Advanced solid tumors（especially Hepatocellular Carcinoma Lung Cancer ） , least one measurable lesion ( RECIST1.1 ) Lack standard treatment treatment failure 1865 year , ECOG PS:01 , Life expectancy 3 month 30 Days last cytotoxic therapy Main organs function normal Women childbearing potential agree use utilize adequate method contraception ( intrauterine device，contraceptive condom ) throughout treatment least 6 month study stopped；the result serum urine pregnancy test negative within 7 day prior study enrollment，and patient require nonlactating；Man participant agree use utilize adequate method contraception throughout treatment least 6 month study stop Patients participate study voluntarily sign informed consent Patients suffer malignancy currently ever , except cured cervical carcinoma situ , nonmelanoma skin cancer Patients factor could affect oral medication ( dysphagia，chronic diarrhea , intestinal obstruction etc . ) Patients participated anticancer drug clinical trial within 4 week Patients participate clinical trial Blood pressure unable control ideally one drug ( systolic pressure≥140 mmHg，diastolic pressure≥90 mmHg ) ; Patients Grade 1 high myocardial ischemia , myocardial infarction malignant arrhythmia ( include male QTc≥450ms , female QTc≥470ms ) patient Grade 1 high congestive heart failure ( NYHA Classification ) Urine protein ≥ ++，and 24hour urinary protein excretion＞1.0 g confirm Patients nonhealing wound fracture Patients drug abuse history unable get rid Patients mental disorder History immunodeficiency Patients concomitant disease could seriously endanger safety could affect completion study accord investigator ' judgment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>